{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:40:21Z","timestamp":1763106021585,"version":"3.40.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03177-9","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T10:09:51Z","timestamp":1721729391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7254-6254","authenticated-orcid":false,"given":"Ruixuan","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"3177_CR1","doi-asserted-by":"crossref","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R et al (2024) European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol.;jdv.19768","DOI":"10.1111\/jdv.19768"},{"issue":"4","key":"3177_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","volume":"12","author":"BA King","year":"2022","unstructured":"King BA, Senna MM, Ohyama M et al (2022) Defining severity in Alopecia Areata: current perspectives and a Multidimensional Framework. Dermatol Ther 12(4):825\u2013834","journal-title":"Dermatol Ther"},{"issue":"3","key":"3177_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR et al (2020) Epidemiology of Alopecia Areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 82(3):675\u2013682","journal-title":"J Am Acad Dermatol"},{"key":"3177_CR4","doi-asserted-by":"crossref","unstructured":"Hyunsun P, Eun KJ, Woong CJ et al Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment. Ann Dermatol 2023;35(3)","DOI":"10.5021\/ad.22.167"},{"key":"3177_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/CCID.S309215","volume":"14","author":"KAL Dillon","year":"2021","unstructured":"Dillon KAL (2021) A comprehensive literature review of JAK inhibitors in treatment of Alopecia Areata. Clin Cosmet Investig Dermatol 14:691\u2013714","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3177_CR6","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and Meta-analyses: The PRISMA Statement. Ann Intern Med 2009;151:264\u2013269.","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"3177_CR7","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"2","key":"3177_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A et al (2021) A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in Alopecia Areata: 24-week results. J Am Acad Dermatol 85(2):379\u2013387","journal-title":"J Am Acad Dermatol"},{"issue":"10387","key":"3177_CR9","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG et al (2023) Efficacy and safety of ritlecitinib in adults and adolescents with Alopecia Areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet 401(10387):1518\u20131529","journal-title":"Lancet"},{"issue":"4","key":"3177_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S et al (2021) Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with Alopecia Areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol 85(4):847\u2013853","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"3177_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O et al (2022) Two phase 3 trials of Baricitinib for Alopecia Areata. N Engl J Med 386(18):1687\u20131699","journal-title":"N Engl J Med"},{"key":"3177_CR12","doi-asserted-by":"publisher","unstructured":"Mahajan R, Daroach M, Handa S et al (2022) Randomized controlled trial to compare the effectiveness and safety of low dose dexamethasone oral mini-pulse versus diphenylcyclopropenone contact sensitisation in severe pediatric alopecia areata. Dermatol Ther [Internet]. 2022 Nov [cited 2024 Feb 18];35(11). https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/dth.15810","DOI":"10.1111\/dth.15810"},{"issue":"4","key":"3177_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000017935","volume":"196","author":"M Pericin","year":"1998","unstructured":"Pericin M, Tr\u00fceb RM (1998) Topical immunotherapy of severe Alopecia Areata with Diphenylcyclopropenone: evaluation of 68 cases. Dermatology 196(4):418\u2013421","journal-title":"Dermatology"},{"issue":"1","key":"3177_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-5945-5-6","volume":"5","author":"S Aghaei","year":"2005","unstructured":"Aghaei S (2005) Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 5(1):6","journal-title":"BMC Dermatol"},{"issue":"6","key":"3177_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2133.1992.tb14877.x","volume":"127","author":"E Hoting","year":"1992","unstructured":"Hoting E, Boehm A (1992) Therapy of Alopecia Areata with diphencyprone. Br J Dermatol 127(6):625\u2013629","journal-title":"Br J Dermatol"},{"issue":"1","key":"3177_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/09546630903410182","volume":"22","author":"N Hunter","year":"2011","unstructured":"Hunter N, Shaker O, Marei N (2011) Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of Alopecia Areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J Dermatol Treat 22(1):2\u201310","journal-title":"J Dermatol Treat"},{"key":"3177_CR17","doi-asserted-by":"crossref","unstructured":"Treatment (1991) of alopecia areata with diphenylcyclopropenone. 24","DOI":"10.1016\/0190-9622(91)70037-3"},{"issue":"2","key":"3177_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2230.1989.tb00915.x","volume":"14","author":"B Monk","year":"1989","unstructured":"Monk B (1989) Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 14(2):154\u2013157","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"3177_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/09546630410023601","volume":"16","author":"F Dall\u2019Oglio","year":"2005","unstructured":"Dall\u2019Oglio F, Nasca MR, Musumeci ML, La Torre G, Ricciardi G, Potenza C et al (2005) Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired\u2010comparison, clinical trial. J Dermatol Treat 16(1):10\u201314","journal-title":"J Dermatol Treat"},{"key":"3177_CR20","doi-asserted-by":"crossref","unstructured":"Rebecca J. Caserio, MD. Treatment of alopecia areata with squaric acid dibutylester. Arch Dermatol 1987;123:1036\u20131041","DOI":"10.1001\/archderm.123.8.1036"},{"key":"3177_CR21","doi-asserted-by":"publisher","first-page":"890027","DOI":"10.3389\/fimmu.2022.890027","volume":"13","author":"SD Jadeja","year":"2022","unstructured":"Jadeja SD, Tobin DJ. Autoantigen discovery in the hair loss disorder, alopecia areata: Implication of post-translational modifications. Front Immunol 2022;13:890027","journal-title":"Front Immunol"},{"issue":"1","key":"3177_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","volume":"49","author":"M Fukuyama","year":"2022","unstructured":"Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022 Jan;49(1):19\u201336","journal-title":"J Dermatol"},{"issue":"12","key":"3177_CR23","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.3390\/cells10123397","volume":"10","author":"A Wa\u015bkiel-Burnat","year":"2021","unstructured":"Wa\u015bkiel-Burnat A, Osi\u0144ska M, Sali\u0144ska A, et al. The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: Clinical implications. Cells 2021;10(12):3397","journal-title":"Cells"},{"key":"3177_CR24","doi-asserted-by":"publisher","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","volume":"13","author":"M Lensing","year":"2022","unstructured":"Lensing M, Jabbari A (2022) An overview of JAK\/STAT pathways and JAK inhibition in Alopecia Areata. Front Immunol 13:955035","journal-title":"Front Immunol"},{"key":"3177_CR25","doi-asserted-by":"crossref","unstructured":"Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol 2024;38(3):583\u2013593","DOI":"10.1111\/jdv.19665"},{"key":"3177_CR26","doi-asserted-by":"crossref","unstructured":"Rastaghi F, Kaveh R, Yazdanpanah N, Sahaf AS, Ahramyanpour N. The efficacy and adverse effects of corticosteroid pulse therapy in alopecia areata: A review article. Dermatol Pract Concept 2023;13(4):e2023255","DOI":"10.5826\/dpc.1304a255"},{"issue":"4","key":"3177_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1468-3083.2011.04114.x","volume":"26","author":"MC Ohlmeier","year":"2012","unstructured":"Ohlmeier MC, Traupe H, Luger TA, B\u00f6hm M (2012) Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata\u2013a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol JEADV 26(4):503\u2013507","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"6","key":"3177_CR28","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","volume":"24","author":"D Dahabreh","year":"2023","unstructured":"Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E (2023) Alopecia Areata: current treatments and new directions. Am J Clin Dermatol 24(6):895\u2013912","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3177_CR29","first-page":"267","volume":"20","author":"A Asilian","year":"2021","unstructured":"Asilian A et al (2021) Oral pulse betamethasone, methotrexate, andcombination therapy to treat severe alopecia areata: a rand-omized, double-blind, placebo-controlled, clinical trial. Iran J Pharm Res 20(1):267\u2013273","journal-title":"Iran J Pharm Res"},{"issue":"7","key":"3177_CR30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","volume":"34","author":"Y Renert-Yuval","year":"2017","unstructured":"Renert-Yuval Y, Guttman-Yassky E (2017) The changing land-scape of Alopecia Areata: the therapeutic paradigm. Adv Ther 34(7):1594\u20131609","journal-title":"Adv Ther"},{"issue":"1","key":"3177_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA et al (2020) The Alopecia Areata Consensus of experts (ACE) study: results of an international expert opinion on treatments for Alopecia Areata. J Am Acad Dermatol 83(1):123\u2013130","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03177-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03177-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T20:40:03Z","timestamp":1725914403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03177-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3177"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03177-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The network meta analysis were performed with published data, ethics committee approval was not required. The study was performed in accordance with the Helsinki Declaration 1964 and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Ruixuan Guan, Yiling Lin, Cun Zhang, Zhao Wang, Zhiping Wu, Xiaojing Liu, Xin Chen and Yongjun Piao declare that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"483"}}